Zejula

Niraparib Tosylate Monohydrate · Poly (ADP-ribose) Polymerase (PARP) Inhibitor

Back to Cancer Drug Encyclopedia Find Recruiting Trials with this Drug →

Indications & Uses

Deleterious BRCA-mutated or HRD-positive Ovarian, Breast, Pancreatic, and Prostate Cancers.

Contraindications

Hypersensitivity to active ingredient or any formulation excipients.

Side Effects & Warnings

Myelosuppression, anemia, fatigue, nausea, vomiting, myelodysplastic syndrome / AML risk.

Drug & Dietary Interactions

Avoid coadministration with strong or moderate CYP3A modulators.

For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.

Patient & Caregiver Support

Ask About This Medication

Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.